Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

[ad_1]


Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.

[ad_2]

Source link